TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29482720

Group type: EXPERIMENTAL
Intervention: Low-dose piperaquine (LD-PIP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 28483414

Group type: EXPERIMENTAL
Intervention: P2-VP8-P[8] subunit rotavirus vaccine (30 μg)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: P2-VP8-P[8] subunit rotavirus vaccine (60 μg)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: P2-VP8-P[8] subunit rotavirus vaccine and Placebo
Number of subjects: 162
Study: 26260973

Group type: EXPERIMENTAL
Intervention: VEINES-QOL questionnaire
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Intrinsic scoring method
Number of subjects: 451
Study: 24131587

Group type: EXPERIMENTAL
Intervention: Universal arm (Triple P - Positive Parenting Program, level 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Universal Plus arm (Triple P - Positive Parenting Program, level 2, level 3, and level 4 group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Services as Usual arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Universal arm, Universal Plus arm, Services as Usual arm
Number of subjects: 0
Study: 21933908

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 420

Group type: COMPARATOR
Intervention: Optimized multiple daily injection (MDI) therapy
Number of subjects: 420
Study: 20467621

Group type: EXPERIMENTAL
Intervention: Bio‐Oss (anorganic bovine bone blocks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Autogenous bone (bone blocks harvested from the iliac crest)
Number of subjects: 10
Study: 15367503

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (45 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11467988

Group type: EXPERIMENTAL
Intervention: Calcium phosphate-adsorbed five-grass-pollen extract
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9488270

Group type: EXPERIMENTAL
Intervention: Surgery for the largest angle measured
Number of subjects: 90

Group type: COMPARATOR
Intervention: Surgery for the initial angle measured at 6 m (Control)
Number of subjects: 90
Study: 8059699

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3046221

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (10 micrograms.kg‐1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Atropine (20 micrograms.kg‐1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 31
Study: 29926478

Group type: EXPERIMENTAL
Intervention: MEDI0382 (5 μg, 10 μg, 30 μg, 100 μg, 150 μg, 300 μg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26358841

Group type: EXPERIMENTAL
Intervention: OKZ 60 mg/120 mg/240 mg every four weeks (Q4W)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: OKZ 60 mg/120 mg every two weeks (Q2W)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 24751388

Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine (5 μg/kg/hour)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine (10 μg/kg/hour)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine (5 μg/kg/hour) and (10 μg/kg/hour)
Number of subjects: 90
Study: 22520118

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV)
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136
Study: 20089065

Group type: EXPERIMENTAL
Intervention: 60-min slides lecture by a military dental practitioner
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group (n = 137) answered the questionnaire
Number of subjects: 336
Study: 18926277

Group type: EXPERIMENTAL
Intervention: Essential newborn care intervention (birth preparedness, clean delivery and cord care, thermal care, breastfeeding promotion, danger sign recognition)
Number of subjects: 104123

Group type: EXPERIMENTAL
Intervention: Essential newborn care plus ThermoSpot (liquid crystal hypothermia indicator)
Number of subjects: 104123

Group type: COMPARATOR
Intervention: Control group (usual services of governmental and non-governmental organisations)
Number of subjects: 104123
Study: 11465644

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (normal-weight women)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: NT-Ob group
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: HT-Ob group
Number of subjects: 49
Study: 9720332

Group type: EXPERIMENTAL
Intervention: 60% lidocaine tape applied for 2.5 hours before venipuncture
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no lidocaine tape)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 60% lidocaine tape
Number of subjects: 71
Study: 7840753

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3277435

Group type: EXPERIMENTAL
Intervention: mezlocillin
Number of subjects: 96

Group type: COMPARATOR
Intervention: clindamycin/gentamicin
Number of subjects: 96
Study: 30736873

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea severity measures (AHI, ODI3%, T90)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Oxygen desaturation index (ODI3%)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Sleep time with SpO2 < 90% (T90)
Number of subjects: 362
Study: 29059694

Group type: EXPERIMENTAL
Intervention: Manual Medicine (MM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 26045510

Group type: EXPERIMENTAL
Intervention: Audience Response System (ARS) embedded in lecture
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no ARS questions)
Number of subjects: 92
Study: 23566745

Group type: EXPERIMENTAL
Intervention: Interferon-α
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ringer's lactate (Control)
Number of subjects: 23
Study: 21849414

Group type: EXPERIMENTAL
Intervention: Cardiovascular exercise (CE; brisk walk on a treadmill)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Hatha yoga (HY)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Nonactivity control condition
Number of subjects: 76
Study: 19361589

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 0
Study: 16626943

Group type: EXPERIMENTAL
Intervention: New time budget measure of activity in psychosis
Number of subjects: 276
Study: 15387960

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 11461714

Group type: EXPERIMENTAL
Intervention: Treatment procedure with accounted measurement error in log-transformed total rapid eye movement (REM) activity counts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Likelihood-based approach accounting for measurement error
Number of subjects: 0
Study: 9159697

Group type: EXPERIMENTAL
Intervention: Nortriptyline pharmacotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Baseline symptoms resembling tricyclic side effects
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Severe depressive episodes and history of anxiety or panic disorder
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dropout before completing acute phase of pharmacotherapy
Number of subjects: 75
Study: 7959619

Group type: EXPERIMENTAL
Intervention: Pulsatile growth hormone (GH) secretion analysis using a computerized mathematical algorithm of pulsatility (Cluster) in children with short stature.
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: GH secretory response to pharmacological stimuli including clonidine, growth hormone-releasing hormone (GHRH), and hypoglycemia after insulin administration in children with short stature.
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group of prepubertal children with normal height and growth velocity.
Number of subjects: 176
Study: 31669916

Group type: EXPERIMENTAL
Intervention: Foot reflexology for five consecutive days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study: 28251260

Group type: COMPARATOR
Intervention: PRP injection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: SVF injection
Number of subjects: 44
Study: 26644225

Group type: COMPARATOR
Intervention: Fixed Dose Combination (FDC) of ceftriaxone and sulbactam
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FDC (3 g/24 h)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FDC (3 g/12 h)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Population-PK model
Number of subjects: 24
Study: 24054792

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 140

Group type: COMPARATOR
Intervention: Open ventral hernia repair
Number of subjects: 140
Study: 22972905

Group type: EXPERIMENTAL
Intervention: Spending time on others
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wasting time
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spending time on oneself
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gaining a windfall of 'free' time
Number of subjects: 0
Study: 20643719

Group type: EXPERIMENTAL
Intervention: EHR-based decision support (clinician reminders and ADHD note template)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: EHR-based decision support (ADHD note template)
Number of subjects: 412
Study: 17947627

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control (ED physician assessment)
Number of subjects: 164
Study: 16648740

Group type: EXPERIMENTAL
Intervention: Low-intensity back school
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299

Group type: COMPARATOR
Intervention: High-intensity back school
Number of subjects: 299
Study: 12671332

Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitor ramipril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta blocker metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dihydropyridine calcium channel blocker amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blood pressure reduction to levels below 92 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary clinical composite end point
Number of subjects: 0
Study: 10870737

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8857906

Group type: EXPERIMENTAL
Intervention: Thoracoscopy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 21
Study: 1623444

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen injections
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo saline injections
Number of subjects: 6
Study: 6503708

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propylthiouracil (PTU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31541364

Group type: EXPERIMENTAL
Intervention: Osteopathic Manual Therapy (OMT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 19
Study: 30360498

Group type: EXPERIMENTAL
Intervention: Peanut group (n = 17)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Almond group (n = 15)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 32
Study: 26892312

Group type: EXPERIMENTAL
Intervention: K305 (3% tetracaine hydrochloride and 0.05% oxymetazoline hydrochloride)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tetracaine hydrochloride spray
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 110
Study: 24985691

Group type: EXPERIMENTAL
Intervention: Unstable shoes (model MBT Fora)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional sports shoes (model Adidas Bigroar)
Number of subjects: 40
Study: 22412842

Group type: EXPERIMENTAL
Intervention: Histologic chorioamnionitis (Grade 1 or Grade 2)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Infection
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Intrapartum fever >38°C
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Epidural for pain relief
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Serum interleukin-8 levels
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Serum interleukin-6 levels
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Admission WBC counts
Number of subjects: 195
Study: 19281600

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 17229406

Group type: EXPERIMENTAL
Intervention: High frequency rTMS over the right DLPFC
Number of subjects: 20

Group type: COMPARATOR
Intervention: SHAM (placebo)
Number of subjects: 20
Study: 15185806

Group type: EXPERIMENTAL
Intervention: Compomer F2000
Number of subjects: 75

Group type: COMPARATOR
Intervention: Amalgam Dispersalloy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Both Compomer and Amalgam
Number of subjects: 75
Study: 12467746

Group type: EXPERIMENTAL
Intervention: Twice weekly oral prednisone (5mg/kg/dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated boys
Number of subjects: 20
Study: 9853999

Group type: EXPERIMENTAL
Intervention: Increased caudal slope of the tibia (group 1)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Patellofemoral pain syndrome (group 2)
Number of subjects: 88
Study: 8132136

Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms t.i.d. s.c. starting at least 1 h before surgery and continued till the 7th postsurgical day
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 2485348

Group type: EXPERIMENTAL
Intervention: Enteral diet rich in fiber (polysaccharides of soya providing 25 gr of dietary fiber per 2,000 kilocalories)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enteral diet poor in fiber (commonly used due to good clinical tolerance)
Number of subjects: 40
Study: 779473

Group type: EXPERIMENTAL
Intervention: Parasympatholytic drug therapy (propantheline bromide or dycyclomine HC1)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Standard surgery
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Medical and surgical therapy
Number of subjects: 210
Study: 30463434

Group type: EXPERIMENTAL
Intervention: Smartphone otoscope
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Conventional otoscope
Number of subjects: 1500
Study: 27670440

Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (current preventive drugs only)
Number of subjects: 80
Study: 25417605

Group type: EXPERIMENTAL
Intervention: Microvascular dissection training on a chicken wing model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group performing endoscopic transantral internal maxillary artery dissection on a silicone-injected anatomical specimen
Number of subjects: 0
Study: 23835722

Group type: EXPERIMENTAL
Intervention: 5 % O(2)
Number of subjects: 258

Group type: COMPARATOR
Intervention: 20 % O(2)
Number of subjects: 258
Study: 22169414

Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study: 19494028

Group type: EXPERIMENTAL
Intervention: CLA-mix (5.5 g/d of 40/40% of cis9,trans11-CLA and trans10,cis12-CLA)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (olive oil)
Number of subjects: 81
Study: 16340945

Group type: EXPERIMENTAL
Intervention: Low-intensity lifestyle intervention
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: High-intensity lifestyle intervention
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: MTHFR TT genotype
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: MTHFR CC/CT genotype
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Changes in biological CVD risk markers
Number of subjects: 915
Study: 17986538

Group type: EXPERIMENTAL
Intervention: Mupirocin ointment applied once daily after routine dressing (Group M)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual daily exit-site care without mupirocin (Group C)
Number of subjects: 154
Study: 11096195

Group type: EXPERIMENTAL
Intervention: PVP-I liposome hydrogel
Number of subjects: 35

Group type: COMPARATOR
Intervention: Bactigras
Number of subjects: 35
Study: 8813867

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untreated short controls
Number of subjects: 15

Group type: COMPARATOR
Intervention: Average controls (10th‐90th centiles)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Both short groups (treated and untreated)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Treated children
Number of subjects: 15
Study: 1399992

Group type: EXPERIMENTAL
Intervention: 4% lidocaine applied to the oral and nasal mucosa
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (sham anesthesia)
Number of subjects: 6
Study: 3895664

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azathioprine and low-dose prednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conversion to Azathioprine (AP)
Number of subjects: 0
Study: 31592887

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 104
Study: 29860967

Group type: EXPERIMENTAL
Intervention: Endovascular strategy (immediate CT followed by endovascular repair if anatomically suitable)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Open repair (CT optional)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Endovascular strategy
Number of subjects: 613

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Endovascular strategy (for proven rupture)
Number of subjects: 613
Study: 28166780

Group type: EXPERIMENTAL
Intervention: High protein diet (1.3 g/kg body weight) with resistance exercise 3 times/week
Number of subjects: 100

Group type: COMPARATOR
Intervention: High protein diet (1.3 g/kg body weight) without resistance exercise
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal protein diet (0.8 g/kg) with resistance exercise 3 times/week
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal protein diet (0.8 g/kg) without resistance exercise
Number of subjects: 100
Study: 25993609

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 24 U (CFL only)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 44 U (CFL + GL)
Number of subjects: 684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study: 23401603

Group type: EXPERIMENTAL
Intervention: Perfusion MRI at rest
Number of subjects: 63
Study: 21910743

Group type: EXPERIMENTAL
Intervention: Ultrasonic irrigation with 1% sodium hypochlorite for 3 min
Number of subjects: 60

Group type: COMPARATOR
Intervention: RinsEndo with 1% sodium hypochlorite for 3 min
Number of subjects: 60
Study: 18059467

Group type: EXPERIMENTAL
Intervention: Amino acid levels on day 7 of age during parenteral nutrition phase
Number of subjects: 122
Study: 16226864

Group type: EXPERIMENTAL
Intervention: Fast spinal injection (20 seconds) of 10 mg of hyperbaric bupivacaine 0.5% with 25 microg of fentanyl and 100 microg of morphine (group R)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Slow spinal injection (60 seconds) of 10 mg of hyperbaric bupivacaine 0.5% with 25 microg of fentanyl and 100 microg of morphine (group L)
Number of subjects: 60
Study: 14505907

Group type: EXPERIMENTAL
Intervention: 0.5mg dose of L2-108/120 peptide
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 0.1mg dose of L2-108/120 peptide
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 11514043

Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae conjugate vaccine
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Vaccine intervention
Number of subjects: 9000
Study: 9032509

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 12
Study: 8286257

Group type: EXPERIMENTAL
Intervention: Topical preparations of highly purified omega-3-PUFA (1% or 10%)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 3492497

Group type: EXPERIMENTAL
Intervention: Urea administered during cardiopulmonary bypass (CPB)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no urea)
Number of subjects: 75
Study: 28944563

Group type: EXPERIMENTAL
Intervention: Levodopa (10 or 15 mg/kg/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 26636922

Group type: EXPERIMENTAL
Intervention: Water-in-oil emulsion
Number of subjects: 0
Study: 24366495

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 83

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 83
Study: 23937996

Group type: EXPERIMENTAL
Intervention: Ketorolac (NSAID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21459451

Group type: EXPERIMENTAL
Intervention: Spectacles + acupuncture (group 2)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Spectacles alone (group 1)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Spectacles alone (group 1) after crossover at 30 weeks
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Spectacles + acupuncture (group 2) after crossover at 30 weeks
Number of subjects: 83